Dr. Joseph Avruch, M.D.
Dr. Avruch is the Chairman of the Mercury Therapeutics Scientific Advisory Board and a co-founder. Dr. Avruch is the Chief of the Diabetes Unit at Massachusetts General Hospital. Dr. Avruch is also an internationally known investigator in the mechanisms of signaling by insulin, growth factors and the role of protein kinases in cell growth and differentiation. Dr. Avruch received the prestigious 2006 Bristol Meyers Squibb Distinguished Investigator Award in Metabolic Disease.
Dr. Bruce Kemp, Ph.D.
Dr. Kemp is one of the world's leading structural biologists in the area of protein kinase signaling. As a principal investigator and co-inventor on the patent claiming the gene sequences for the AMP kinase patent licensed by MTI, Dr. Kemp is a member of the Mercury Therapeutics Scientific Advisory Board and directs a laboratory at St. Vincent's Institute for Medical Research in Melbourne, Australia whose main focus is the determination of the 3-dimensional structure of AMP-activated protein kinase.
Dr. John Kyriakis, Ph.D.
Dr. Kyriakis is a Professor of Molecular Cardiology at Tufts New England Medical Center and a discoverer and an internationally recognized authority in the MAP kinase signal transduction pathway and inflammation. Dr. Kyriakis' research has led to fundamental discoveries in signal transduction with potential applications in metabolic disease, cancer, and rheumatology. He has authored over 80 manuscripts published in peer-reviewed journals.